CUNEO, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 24.578
EU - Europa 7.362
AS - Asia 7.193
SA - Sud America 416
AF - Africa 40
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 13
Totale 39.617
Nazione #
US - Stati Uniti d'America 24.482
SG - Singapore 2.788
CN - Cina 2.665
UA - Ucraina 1.706
DE - Germania 1.642
IT - Italia 1.269
TR - Turchia 1.177
GB - Regno Unito 708
FI - Finlandia 524
SE - Svezia 400
BR - Brasile 380
PL - Polonia 364
FR - Francia 233
ID - Indonesia 198
RU - Federazione Russa 143
VN - Vietnam 134
BE - Belgio 89
HK - Hong Kong 89
NL - Olanda 79
CZ - Repubblica Ceca 69
CA - Canada 68
IN - India 36
AT - Austria 35
LT - Lituania 30
ZA - Sudafrica 18
ES - Italia 14
JP - Giappone 14
MX - Messico 14
IR - Iran 12
AU - Australia 11
IE - Irlanda 11
AR - Argentina 10
EU - Europa 10
IQ - Iraq 9
RO - Romania 9
UZ - Uzbekistan 9
BD - Bangladesh 8
EC - Ecuador 8
MA - Marocco 8
IL - Israele 7
PK - Pakistan 7
AZ - Azerbaigian 6
CH - Svizzera 6
KR - Corea 6
PE - Perù 5
PH - Filippine 5
BO - Bolivia 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
JO - Giordania 4
NZ - Nuova Zelanda 4
TN - Tunisia 4
VE - Venezuela 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
BY - Bielorussia 3
DZ - Algeria 3
HR - Croazia 3
MK - Macedonia 3
PT - Portogallo 3
CL - Cile 2
EE - Estonia 2
GT - Guatemala 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
NI - Nicaragua 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
TW - Taiwan 2
BH - Bahrain 1
CO - Colombia 1
EG - Egitto 1
GR - Grecia 1
HN - Honduras 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
QA - Qatar 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TG - Togo 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 39.617
Città #
Fairfield 3.015
Woodbridge 2.968
Houston 1.998
Jacksonville 1.857
Chandler 1.676
Ann Arbor 1.362
Ashburn 1.335
Santa Clara 1.290
Singapore 1.194
Seattle 1.157
Wilmington 1.125
Cambridge 976
Izmir 644
Nanjing 592
Beijing 567
Princeton 480
Warsaw 355
San Diego 311
Boardman 307
Ferrara 274
New York 225
Milan 219
Shanghai 204
Jakarta 189
Shenyang 188
Nanchang 172
Munich 162
Helsinki 143
Dong Ket 132
Hebei 128
Los Angeles 120
Bremen 115
Addison 113
Changsha 97
Tianjin 93
Falls Church 88
Jiaxing 87
Brussels 86
Hong Kong 85
Dearborn 83
London 73
Jinan 71
Mountain View 69
Redwood City 63
Zhengzhou 63
Norwalk 55
Brno 47
Kunming 46
San Mateo 46
Toronto 42
Ningbo 40
Falkenstein 38
Guangzhou 37
Bologna 35
Frankfurt am Main 35
Rome 35
Orange 34
São Paulo 30
Nuremberg 29
Des Moines 28
Washington 28
Auburn Hills 27
Lappeenranta 27
Taizhou 25
Tappahannock 25
Verona 24
Chicago 23
Augusta 22
Hangzhou 21
Indiana 21
Ottawa 21
Changchun 20
Olomouc 19
Florence 18
Lanzhou 18
Philadelphia 18
Haikou 17
Parma 17
Fidenza 16
Leawood 16
San Francisco 16
Vienna 16
Redmond 15
Napoli 14
Hefei 13
San Jose 13
Kilburn 11
Lozzo Atestino 11
Newark 11
Bari 10
Council Bluffs 10
Naples 10
Prineville 10
Rio de Janeiro 10
Springfield 10
Belo Horizonte 9
Modena 9
Mumbai 9
Amsterdam 8
Dublin 8
Totale 27.774
Nome #
A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. 301
Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders 213
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI 203
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation 196
The anti-leukemic activity of sodium dichloroacetate in p53(mutated/null) cells is mediated by a p53-independent ILF3/p21 pathway 193
CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis 193
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 182
Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3 181
13q14 deletions in chronic lymphoproliferative disorders with the t(11;14)(q13;q32): a cytogenetic and interphase cytogenetic study. 173
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 172
Diagnostic work-up for clinical and prognostic assessment of acute leukaemia 171
13q14 deletion in non-Hodgkin's lymphoma: Correlation with clinicopathologic features 170
The active metabolite of warfarin (3′-hydroxywarfarin) and correlation with INR, warfarin and drug weekly dosage in patients under oral anticoagulant therapy: A pharmacogenetics study 169
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia 165
MORFOLOGIA E FISIOPATOLOGIA DEL SANGUE E DEGLI ORGANI EMOPOIETICI 157
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells 156
Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: Correlation with clinicobiologic features 155
Thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans retinoic acid treatment: a case report. 155
A novel t(9;11)(p22;q23) with ALL-1 gene rearrangement associated with progression of a myeloproliferative disorder to acute myeloid leukemia 154
A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs 154
Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML 154
P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia 154
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 153
5' region and exon 7 mutations of the TP53 gene in two cases of B-cell prolymphocytic leukemia. 153
The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias 153
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 152
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations 150
Novel small deletions of the p53 gene in late stage B-cell chronic lymphocytic leukaemia 149
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 149
Acute Human Herpesvirus-6A infection of human mesothelial cells modulates HLA molecules 149
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 148
Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype 147
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 146
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients 146
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 146
CYTOGENETIC ABERRATIONS IN THE CD38 POSITIVE FRACTION OF CD38 NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A MARKER OF AGGRESSIVENESS? 145
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in SplenicMarginal Zone Lymphoma 144
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy 143
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 143
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 143
Tryptase-positive mast cells predict clinical outcome of patients with early B-cell chronic lymphocytic leukemia 142
Chromosome aberrations in atypical chronic lymphocytic leukemia: a cytogenetic and interphase cytogenetic study 141
Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies. 141
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 141
Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: Comparison with metaphase banding analysis 139
Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. 139
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 138
Minimal morphological criteria for defining bone marrow dysplasia: A basis for clinical implementation of WHO classification of myelodysplastic syndromes 136
Ibrutinib in the real world patient: Many lights and some shades 136
BCR/ABL1-positive acute lymphoblastic leukemia relapsing as BCR/ABL1-negative acute lymphoblastic leukemia 135
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations 135
Waldenstrom macroglobulinemia 134
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 133
A novel translocation t(1;7)(p36;q34) in three patients with acute myeloid leukaemia 132
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. 131
In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome 131
A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma 130
Exercise training and endothelial progenitor cells in haemodialysis patients 130
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 130
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 128
REFINED KARYOTYPE-BASED PROGNOSTIC STRATIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH A VERY LOW RISK GENETIC PROFILE 128
Interleukin-3 plus interleukin-6 may improve chromosomal analysis of multiple myeloma: Cytologic and cytogenetic evidence in thirty-four patients 127
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z) 127
Delirium in acute promyelocytic leukemia patients: two case reports. 127
[Use of 5-phosphodiesterase inhibitors in patients with LUTS secondary to BPH: our experience and review of the literature]. 125
null 124
In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34+ cells. 123
Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome on behalf of the GIMEMA chronic lymphoproliferative diseases working group 123
Neoplastic circulating endothelial-like cells in patients with acute myeloid leukaemia. 122
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 122
Dendritic cells in acute promyelocytic leukaemia 122
Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia 122
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 122
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. 122
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 121
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 121
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 121
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study 121
Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. 121
Hepatosplenic T-cell lymphoma (HSTCL). 120
Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: study of nine cases 120
B-Cell chronic lymphocytic leukemia (B-CLL) with 14q32 translocations: haematological features and clinical outcome. 119
Richter's syndrome in a case of atypical chronic lymphocytic leukaemia with the t(11;14)(q13;q32): role for a p53 exon 7 gene mutation 119
Etiology of Febrile Episodes in Patients With Acute Myeloid Leukemia: Results From the Hema e-Chart Registry 119
Myelofibrosis with Myeloid Metaplasia (MMM)/Idiopathic myelofibrosis/Agnogenic myeloid metaplasia 119
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 118
A prospective survey of febrile events in hematological malignancies 118
Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial) 118
null 118
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients 116
Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. 116
Minor myeloid component in Ph chromosome-positive acute lymphoblastic leukaemia: correlation with cytogenetic pattern and implication for poor response to therapy 115
Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol 115
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features 115
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB 115
Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome 115
Mucosa-associated lymphoid tissue (MALT) lymphoma. 114
Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case 114
t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia 114
Cytogenetics in myelodysplastic syndromes: Old methods, new clues 114
Totale 14.074
Categoria #
all - tutte 216.658
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 25.508
Totale 242.166


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.275 0 0 0 0 0 0 0 0 0 810 333 132
2020/20215.638 418 469 311 546 275 620 206 639 109 802 779 464
2021/20224.235 230 531 203 195 226 230 230 260 138 359 427 1.206
2022/20234.073 500 178 138 464 698 594 181 363 560 21 250 126
2023/20242.042 186 284 97 50 128 283 89 111 65 55 79 615
2024/20256.581 315 200 787 324 1.145 746 242 510 1.537 775 0 0
Totale 40.364